Bionano net loss widens 8.26% to $7.42 million in Q2 FY26; revenue rises 21% to $8.2 million
Reuters2026/08/10 20:12- Bionano Genomics reported Q2 revenue of USD 8.2 million, up 21% year over year, as consumables rose 31% to USD 4.3 million.
- Net loss widened to USD 7.42 million, while gross margin edged up 1 percentage point to 53%.
- Flow-cell volume climbed 27% to 9,219, while operating expenses increased 2% to USD 11.5 million.
- Management cited accelerating global adoption of optical genome mapping, driven mainly by increased clinical adoption and higher utilization at clinical sites.
- Issued Q3 revenue guidance of USD 8.2 million-USD 8.6 million, maintaining full-year guidance of USD 31 million-USD 33 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Apple showcases its foldable screen iPhone; analysts see potential but warn of profit margin risks
Bloomberg Intelligence has raised its first-year sales estimate for the iPhone Duo to approximately 14 million units, with potential revenue reaching $28 billion. However, the pricing strategy has raised concerns in the market: the iPhone 17 and Air series will maintain their original prices, while the increase for the Pro series is lower than expected. Amid rising supply chain costs, this puts significant pressure on profit margins. Analysts believe that Apple aims to trade profit margin for sales volume and offset the pressure by driving an optimized mix of high-end models.
AutoNation CFO Tom Szlosek to speak at Morgan Stanley Laguna Conference fireside chat
Simon Property Group agrees to sell USD 800 million senior notes
Crypto prices
More
